- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2013.
- Why 4/10
- BAT is already FDA-approved (since 2013) and commercially marketed with no pending regulatory decision or pivotal readout scheduled. The next hard catalyst would be a major U.S. government contract award or modification, which is not a dated binary event. Per the impact score rubric, an approved drug with no pending regulatory decision scores 3-5, and BAT is one of several products in Emergent's diversified portfolio, not the sole value driver.
BAT is an already-approved, marketed product with no pending FDA decision. The next catalyst for Emergent is not BAT-specific but rather the pace of U.S. government contract awards and international orders, which drive lumpy quarterly revenue. Watch for further ASPR contract modifications or international BAT orders, as well as the company's Q4 2026 earnings for updates on the full-year guidance trajectory.
Price Chart
Executive Summary
BAT (Botulism Antitoxin Heptavalent) is an equine-derived antitoxin that neutralizes all seven known botulinum neurotoxin serotypes. It was originally developed by Cangene Corporation and approved by the FDA in March 2013 under the Animal Rule as a biodefense medical countermeasure. Emergent BioSolutions (NYSE: EBS), which acquired Cangene, now manufactures and markets BAT exclusively to government stockpiles. BAT is the only FDA-approved product for treating symptomatic botulism in adults across all serotypes. Revenue is lumpy and tied to U.S. government procurement contracts; a $64.5 million ASPR contract modification was awarded in May 2026. In Q3 2026, BAT sales fell sharply due to timing of government deliveries, contributing to a 52% overall revenue decline for Emergent. The drug has no pending FDA regulatory decision, making it a stable but low-growth asset within Emergent's broader biodefense portfolio.
How It Works
BAT is an antitoxin made from antibodies harvested from horses that have been immunized against botulinum toxins. When injected into a patient with botulism, these antibodies bind to and neutralize the free-floating botulinum nerve toxins in the bloodstream, preventing them from causing further damage. It covers all seven known botulinum toxin types (A through G). It does not reverse damage already done by the toxin, so it must be given as early as possible after symptoms appear.
Trial Status
BAT was approved by the FDA on March 22, 2013, under the Animal Rule (efficacy established in animal models). It is also approved by Health Canada. No active clinical trials are ongoing for the approved indication; the drug is commercially available and distributed through the CDC for use in suspected or confirmed botulism cases.
The Two-Sided Case
Upcoming Catalysts
- U.S. government (ASPR) contract modifications or new awards for BAT stockpile replenishment
- International government BAT orders (the company noted increased international sales in Q3 2026)
- Emergent Q4 2026 earnings (early 2027) for BAT revenue and full-year 2027 guidance
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report